Alcon to acquire STAAR Surgical for $28/share in cash, ~$1.5B equity value

STAAR SURGICAL CO

Alcon pays $28/share cash, a ~59% premium to STAAR's 90-day VWAP and 51% premium to Aug 4 close.
Transaction valued at ~$1.5B equity; Alcon will fund via short- and long-term credit facilities.
Expected to close in 6–12 months, subject to regulatory approvals and STAAR shareholder vote.
STAAR's board unanimously approved; deal is not subject to financing condition and expected to be accretive in year two.
STAAR will release Q2 results on Aug 6, 2025 but will not host a conference call due to pending acquisition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.